VERAXA Biotech (NASDAQ: VRXA) has announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program in collaboration with ATUM. The partnership will leverage ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines that support IND/CTA-enabling activities and future clinical development. This move follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. This innovation addresses a key limitation of current T-cell engagers, which often cause severe side effects due to activation on healthy cells.
The collaboration with ATUM is a critical step in advancing the BiTAC-TCE program toward clinical trials. By developing stable cell lines early, VERAXA aims to streamline the manufacturing process and ensure consistent product quality. The company emphasizes that this approach aligns with its quality-by-design principles, which guide the development of its pipeline of antibody-based therapeutics, including bispecific T-cell engagers and bispecific ADCs.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). The company's proprietary BiTAC(R) technology is a registered trademark of VERAXA Biotech GmbH. For more details, the full press release is available at https://ibn.fm/FCIlk.
This development is significant because it moves VERAXA's novel cancer therapy approach from preclinical research into the manufacturing and development phase, bringing it closer to potential clinical application. If successful, the BiTAC-TCE platform could offer a safer and more effective option for patients, particularly those with solid tumors where conventional T-cell engagers have limited success.
